Patents Assigned to Genentech
  • Hindered disulfide drug conjugates
    Patent number: 10729738
    Abstract: The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Jinhua Chen, John Wai
  • Anti-OX40 antibodies and methods of use
    Patent number: 10730951
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Changchun Du, Jeong Kim, Jing Zhu, Jack Bevers, III, Kevin Walsh, Patricia De Almeida, James Andya, Ye Shen
  • Amido spirocyclic amide and sulfonamide derivatives
    Patent number: 10730889
    Abstract: Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 4, 2020
    Assignees: FORMA TM, LLC, Genentech, Inc.
    Inventors: Kenneth W. Bair, Timm R. Baumeister, Peter Dragovich, Xiongcai Liu, Snahel Patel, Po-Wai Yuen, Mark Zak, Guiling Zhao, Yamin Zhang, Xiaozhang Zheng
  • Apparatus and methods for sealing a medicament within a medical delivery device
    Patent number: 10729616
    Abstract: Apparatus and methods for lyophilizing and sealing a medicament within a medical delivery device having an opening. The apparatus may include a stopper for sealing the opening. The stopper may have one or more elongated members extending from a base, in a direction that is parallel to a central axis of the base. One or more of the members may be set radially away from the axis and define a coaxial central well. The member or members may define a void. The elongated member or members may engage a device inner wall and support the base away from the opening. The void may provide gas exchange between a device interior and a device exterior. The gas may be a lyophilization byproduct that escapes from the device interior between the inner wall, the base and the member or members. The stopper may be advanced into the device to seal the opening.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventor: Lionel Vedrine
  • TREATMENT OF ADVANCED HER2 EXPRESSING CANCER
    Publication number: 20200237910
    Abstract: Methods for the treatment of patients with HER2-positive, HER2-amplified and/or HER2-mutated advanced cancer by administration of pertuzumab plus trastuzumab are disclosed. In one aspect, the cancer is advanced HER2-positive, HER2-amplified and/or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer. In another aspect, the cancer is HER2-positive, HER2-amplified and/or HER2-mutated colorectal, biliary, bladder, urothelial, salivary, lung, pancreatic, ovarian, prostate, or skin cancer that is refractory to one or more other treatment regimens.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 30, 2020
    Applicant: GENENTECH, INC.
    Inventors: Mary Beattie, Melissa Brammer
  • FIXED DOSING OF HER ANTIBODIES
    Publication number: 20200239595
    Abstract: The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab.
    Type: Application
    Filed: December 10, 2019
    Publication date: July 30, 2020
    Applicant: Genentech, Inc.
    Inventors: DAVID E. ALLISON, RENE BRUNO, JIAN-FENG LU, CHEE M. NG
  • Anti-interleukin-33 antibodies and uses thereof
    Patent number: 10723795
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
  • HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS
    Publication number: 20200222547
    Abstract: The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.
    Type: Application
    Filed: September 19, 2019
    Publication date: July 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Sebastian STARK, Thomas KNAPPE, Harald RAU, Nicola BISEK, Burkhardt LAUFER, Samuel WEISBROD, Tobias VOIGT, Germaine FUH, Patrick KOENIG, Chingwei Vivian LEE, Daniela BUMBACA YADAV
  • SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20200222545
    Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: Genentech, Inc.
    Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
  • Ionic strength-mediated pH gradient ion exchange chromatography
    Patent number: 10712322
    Abstract: The present invention provides methods for analyzing compositions of polypeptides such as antibodies by ionic strength-mediated pH gradient ion exchange chromatography. In some aspects, the methods use a combination of pH gradients and ionic strength gradients to separate the polypeptide from charge variants of the polypeptide. In some aspects, the methods use a stable ionic strength to optimize the pH gradient separation window to separate the polypeptide from charge variants. Such methods are useful for analyzing polypeptide, e.g. antibodies, with a pI greater than 9 or a pI less than 7. In some aspects, the invention provides a multiproduct method for the analysis of polypeptides of varying pI's.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Yajun Wang, George Tony Moreno, Boyan Zhang, Liangyi Zhang, Dell Farnan, Thomas Patapoff
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10710994
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
  • Oxadiazole transient receptor potential channel inhibitors
    Patent number: 10711004
    Abstract: The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: July 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Brian Safina, Daniel Shore, Jack Terrett, Elisia Villemure, Matthew Volgraf, Stuart Ward, Aijun Lu, Robin Larouche-Gauthier, Francis Beaumier, Martin Dery, Lea Constantineau-Forget, Chantal Grand-Maitre, Luce Lepissier
  • Anti-Tau antibodies and methods of use
    Patent number: 10711058
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: July 14, 2020
    Assignees: AC Immune SA, Genentech, Inc.
    Inventors: Oskar Adolfsson, Isidro Hotzel, Danielle DiCara
  • METHODS FOR VIRAL INACTIVATION AND OTHER ADVENTITIOUS AGENTS
    Publication number: 20200216799
    Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
    Type: Application
    Filed: July 18, 2019
    Publication date: July 9, 2020
    Applicant: Genentech, Inc.
    Inventors: Masaru Ken SHIRATORI, Robert David KISS, Hardayal PRASHAD, Raquel IVERSON, Justin BOURRET, Michael KIM, Salim CHARANIYA
  • FORMULATIONS WITH REDUCED DEGRADATION OF POLYSORBATE
    Publication number: 20200215195
    Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.
    Type: Application
    Filed: November 21, 2019
    Publication date: July 9, 2020
    Applicant: Genentech, Inc.
    Inventors: Brian CONNOLLY, Lydia HAMBURG, Emily HOLZ
  • Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
    Patent number: 10704071
    Abstract: The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: July 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Meixia Zhou, Bradley Richard Snedecor, Chi Kin Domingos Ng, Amy Shen
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20200206348
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Jayantha Ratnayake, Graham A. Ross
  • Therapeutic compounds and uses thereof
    Patent number: 10696655
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 30, 2020
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Sulfonyl pyridyl TRP inhibitors
    Patent number: 10695348
    Abstract: The invention provides compounds of formula I: and pharmaceutically acceptable salts thereof where R1 is a substituted or unsubstituted phenyl or a fused bicyclic comprising a substituted or unsubstituted phenyl. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 30, 2020
    Assignee: Genentech, Inc.
    Inventors: Vishal Verma, Matthew Volgraf, Baihua Hu
  • Cystine knot scaffold platform
    Patent number: 10696721
    Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 30, 2020
    Assignee: Genentech, Inc.
    Inventors: Rami Hannoush, Harini Kaluarachchi, Aaron Nile, Cameron Noland, Yingnan Zhang, Lijuan Zhou, Xinxin Gao